Learn how glaucoma and diabetic retinopathy silently threaten your eyesight and discover simple ways to protect your vision ...

The market is projected to grow at a compound annual growth rate (CAGR) of approximately 6.4% from 2025 to 2035, increasing from USD 18466.9 Million in 2025 to USD 34340.7 Million by 2035.

Type 2 diabetes isn’t just a condition, it’s a long-term health risk that evolves silently. Timely testing, accurate readings ...

Disorganization of retinal inner layers (DRIL) is likely an important biomarker signaling visual deterioration in patients with diabetic macular ischemia (DMI), and overall causes for functional ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Investigators examined GLP-1 receptor agonist real-world effectiveness and safety in kidney transplant recipients with diabetes.

A new study found a link between GLP-1s and a higher risk of neovascular age-related macular degeneration, an eye disease ...

LAS VEGAS, NEVADA / ACCESS Newswire / June 10, 2025 / Avant Technologies Inc. (OTCQB:AVAI) (“Avant” or the “Company”), and ...

Current technologies, and those in the pipeline and beyond, could advance the management of diabetes comorbidities, George Grunberger, MD, FACP, FACE, said during a presentation at the Heart in ...

Semaglutide, widely used to treat diabetes and obesity, was associated with more than double the risk of developing ...

HealthDay News — For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased risk for incident neovascular age-related macular ...

Diabetic retinopathy, a common complication of diabetes, can damage the retina and lead to blindness. Early symptoms like ...